Please assess the completion status of the following clinical trial:

Trial Title: Lipoprotein Apheresis in Refractory Angina Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients diagnosed with refractory angina for more than three months.~* Two or more episodes of angina per week.~* Previous history of myocardial infarction, coronary artery bypass graft (CABG) surgery,percutaneous coronary intervention (PCI) or any combination of the above.~* Prescribed optimal medical therapy.~* Hypercholesterolaemia with an elevated Lp(a) \> 50mg/dL and an LDL-cholesterol less than 4.0mmol/L despite optimal lipid lowering drug therapy.~Exclusion Criteria:~* Patients with poor calibre veins for cannulation.~* Patients with any other chronic systemic illness such as liver or renal failure, neoplastic disease, overt cardiac failure, unstable coronary artery disease, coronary revascularisation or a myocardial infarction within the previous eight weeks.~* Pregnancy, untreated diabetes mellitus, untreated arterial hypertension, and those with general contraindications to undergoing Cardiovascular magnetic resonance imaging or contraindications to adenosine.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- First Lipoprotein Apheresis, then sham apheresis (Type: ACTIVE_COMPARATOR): Three months of weekly lipoprotein apheresis, 1 month washout, then three month sham apheresis
- First Sham Apheresis, then Lipoprotein Apheresis (Type: SHAM_COMPARATOR): Three months of weekly sham apheresis, 1 month washout, then three month lipoprotein Apheresis

Based on this trial design, predict the completion outcome and termination type (if applicable).